Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper
Author:
Affiliation:
1. From the Department of Medicine, Divisions of Hematology and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/96/5/1698/1667169/h8170001698.pdf
Reference35 articles.
1. Coagulation factors V and VIII: normal function and clinical disorders.;White,1995
2. Mortality before and after HIV infection in the complete UK population of haemophiliacs. UK Haemophilia Centre Directors' Organisation [see comments].;Darby;Nature.,1995
3. Prophylactic use of factor VIII: an economic evaluation.;Bohn;Thromb Haemost.,1998
4. Hemophilia home treatment. Economic analysis and implications for health policy.;Ross-Degnan;Int J Technol Assess Health Care.,1995
5. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates.;Scharrer;Haemophilia.,1999
Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting;Thrombosis Research;2024-05
2. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A;Journal of Medicine and Life;2022-04
3. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective;Blood;2021-11-04
4. Costs and management of patients with hemophilia A in France: the Hemraude study;The European Journal of Health Economics;2021-07-08
5. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A;DARU Journal of Pharmaceutical Sciences;2020-04-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3